Etiology, pathophysiology, and treatment of Atrial fibrillation part 1

Cardiology in Review

Volumn 16, Issue 4, 2008, Pages 181-188

  Aronow, Wilbert S ^a  

^a WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Beta blockers; Calcium channel blockers; Cardiovascular disease; Cardioversion; Digoxin; Pacemakers; Radiofrequency catheter ablation; Stroke

Indexed keywords

ACETYLCHOLINE; ADENOSINE; AMINOPHYLLINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ARBUTAMINE; ATENOLOL; CISPLATIN; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOCETAXEL; DOPAMINE; DOPEXAMINE; ETOPOSIDE; FLOSEQUINAN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; ISOSORBIDE MONONITRATE; LOSARTAN; MELPHALAN; METHYLPREDNISOLONE; PERFLEXANE; PERFLUBUTANE; PSEUDOEPHEDRINE; SALBUTAMOL; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VERAPAMIL; AMIODARONE; ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ARTIFICIAL HEART PACEMAKER; BRAIN INFARCTION; CATHETER ABLATION; CATHETER OCCLUSION; CLINICAL FEATURE; DISEASE PREDISPOSITION; DOPPLER ECHOCARDIOGRAPHY; DRUG MEGADOSE; ELECTROCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HUMAN; MITRAL VALVE; MORBIDITY; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK FACTOR; STROKE; CARDIOVERSION; DRUG COMBINATION; METHODOLOGY; TREATMENT OUTCOME;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CATHETER ABLATION; DILTIAZEM; DRUG THERAPY, COMBINATION; ELECTRIC COUNTERSHOCK; HUMANS; PACEMAKER, ARTIFICIAL; TREATMENT OUTCOME; VERAPAMIL;

EID: 49149104567     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31816de1e3     Document Type: Review

References (85)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
2. Aronow WS, Ahn C, Gutstein H. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. J Am Geriatr Soc. 1996;44:521-523.
3. Aronow WS, Ahn C, Gutstein H. Prevalence and incidence of cardiovascular disease in 1, 160 older men and 2, 464 older women in a long-term health care facility. J Gerontol Med Sci. 2002;57A:M45-M46.
4. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74:236-241.
5. Mendelson G, Aronow WS. Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke. J Am Geriatr Soc. 1998;46:1423-1424.
6. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455-2461.
7. Danias PG, Caulfield TA, Weigner MJ, et al. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol. 1998;31:588-592.
8. Konings KTS, Kirchhof CJ, Smeets JR, et al. High-density mapping of electrically induced atrial fibrillation in humans. Circulation. 1994;89: 1665-1680.
9. Jais P, Haissaguerre M, Shah DC, et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation. 1997;95:572-576.
10. Allessie MA, Boyden PA, Camm AJ, et al. Pathophysiology and prevention of atrial fibrillation. Circulation. 2001;103:769-777.
11. Mitchell GF, Vasan RS, Keyes MJ, et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA. 2007;297:709-715.
12. Ellinor PT, Low A, Patton KK, et al. C-reactive protein in lone atrial fibrillation. Am J Cardiol. 2006;97:1346-1350.
13. Osranek M, Fatema K, Qaddoura F, et al. Left atrial volume predicts the risk of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2006;48:779-786.
14. Aronow WS, Ahn C, Kronzon I. Echocardiographic findings associated with atrial fibrillation in 1, 699 patients aged >60 years. Am J Cardiol. 1995;76:1191-1192.
15. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentration as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249-1252.
16. van der Hooft CS, Heeringa J, van Herpen G, et al. Drug-induced atrial fibrillation. J Am Coll Cardiol. 2004;44:2117-2124.
17. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. A meta-analysis. J Am Coll Cardiol. 2005;45:1832-1839.
18. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 1982; 306:1018-1022.
19. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death. The Framingham Heart Study. Circulation. 1998;98:946-952.
20. Aronow WS, Ahn C, Mercando AD, et al. Correlation of atrial fibrillation, paroxysmal supraventricular tachycardia, and sinus rhythm with incidences of new coronary events in 1, 359 patients, mean age 81 years, with heart disease. Am J Cardiol. 1995;75:182-184.
21. Friberg J, Scharling H, Gadsboll N, et al. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (the Copenhagen City Heart Study). Am J Cardiol. 2004; 94:889-894.
22. Dagres N, Nieuwlaat R, Vardas PE, et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe. A report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol. 2007;49:572-577.
23. Rathore SS, Berger AK, Weinfurt KP, et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation. 2000;101:969-974.
24. Wong C-K, White HD, Wilcox RG, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J. 2000;140:878-885.
25. Al-Khatib SM, Pieper KS, Lee KL, et al. Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial. Am J Cardiol. 2001;88:76-79.
26. Aronow WS, Ahn C, Mercando AD, et al. Correlation of paroxysmal supra-ventricular tachycardia, atrial fibrillation, and sinus rhythm with incidences of new thromboembolic stroke in 1, 476 old-old patients. Aging/Clin Exp Res. 1996;8:32-34.
27. Aronow WS, Ahn C, Kronzon I, et al. Association of left ventricular hypertrophy and chronic atrial fibrillation with the incidence of new thromboembolic stroke in 2, 384 older persons. Am J Cardiol. 1999;84: 468-469.
28. Aronow WS, Ahn C, Schoenfeld MR, et al. Association of extracranial carotid arterial disease and chronic atrial fibrillation with the incidence of new thromboembolic stroke in 1, 846 older persons. Am J Cardiol. 1999;83:1403-1404.
29. Planning and Steering Committees for AFFIRM Study. Atrial fibrillation follow-up investigation of rhythm management-the AFFIRM Study design. Am J Cardiol. 1997;79:1198-1202.
30. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
31. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
32. Aronow WS, Ahn C, Kronzon I, et al. Risk factors for new thromboembolic stroke in persons ≥62 years old with chronic atrial fibrillation. Am J Cardiol. 1998;82:119-121.
33. Aronow WS, Gutstein H, Hsieh FY. Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. Am J Cardiol. 1989;63:366-367.
34. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. II. Echocardiocardiographic features of patients at risk. Ann Intern Med. 1992;116:6-12.
35. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for highrisk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-638.
36. Aronow WS, Ahn C, Kronzon I, et al. Effect of warfarin versus aspirin on the incidence of new thromboembolic stroke in older persons with chronic atrial fibrillation and abnormal and normal left ventricular ejection fraction. Am J Cardiol. 2000;85:1033-1035.
37. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. I. Clinical features of patients at risk. Ann Intern Med. 1992;116:1-5.
38. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
39. Aronow WS, Ahn C, Kronzon I, et al. Association of mitral annular calcium with new thromboembolic stroke at 44-month follow-up of 2, 148 persons, mean age 81 years. Am J Cardiol. 1998;81:105-106.
40. Peterson P, Kastrup J, Helweg-Larsen S, et al. Risk factors for thromboembolic complications in chronic atrial fibrillation. Arch Intern Med. 1990;150:819-821.
41. Jozwiak A, Guzik P, Mathew A, et al. Association of atrial fibrillation and focal neurologic deficits with impaired cognitive function in hospitalized patients ≥65 years of age. Am J Cardiol. 2006;98:1238-1241.
42. Yamanouchi H, Mizutani T, Matsushita S, et al. Paroxysmal atrial fibrillation: high frequency of embolic brain infarction in elderly autopsy patients. Neurology. 1997;49:1691-1694.
43. Ezekowitz MD, James KE, Nazarian SM, et al. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. Circulation. 1995;92: 2178-2182.
44. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol. 1998;32:695-703.
45. Aronow WS, Ahn C, Kronzon I. Prognosis of congestive heart failure after prior myocardial infarction in older persons with atrial fibrillation versus sinus rhythm. Am J Cardiol. 2001;87:224-225.
46. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke. Results from the national registry of atrial fibrillation. JAMA. 2001;285:2864-2870.
47. Khumri TM, Idupulapati M, Rader VJ, et al. Clinical and echocardiographic markers of mortality risk in patients with atrial fibrillation. Am J Cardiol. 2007;99:1733-1736.
48. Shinbane JS, Wood MA, Jensen DN, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709-715.
49. Schumacher B, Luderitz B. Rate issues in atrial fibrillation: consequences of tachycardia and therapy for rate control. Am J Cardiol. 1998;82:29N-36N.
50. Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation. 2000;101:1138-1144.
51. Redfield MM, Kay GN, Jenkins LS, et al. Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc. 2000;75:790-795.
52. Jahangir A, Lee V, Friedman PA, et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow up study. Circulation. 2007;115:3050-3056.
53. Ellis K, Ziada KM, Vivekananthan D, et al. Transthoracic echocardiographic predictors of left atrial appendage thrombus. Am J Cardiol. 2006;97:421-425.
54. Pollak A, Falk RH. Pacemaker therapy in patients with atrial fibrillation. Am Heart J. 1993;125:824-830.
55. Morady F, Hasse C, Strickberger SA, et al. Long-term follow-up after radiofrequency modification of the atrioventricular node in patients with atrial fibrillation. J Am Coll Cardiol. 1997;27:113-121.
56. Feld GK, Fleck P, Fujimura O, et al. Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. Circulation. 1994;90:2299-2307.
57. Fitzpatrick AP, Kourouyan HD, Siu A, et al. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J. 1996;131:499-507.
58. Brignole M, Menozzi C, Gianfranchi L, et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation. A randomized, controlled study. Circulation. 1998;98:953-960.
59. Ozcan C, Jahangir A, Friedman PA, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med. 2001;344: 1043-1051.
60. Channamsetty V, Aronow WS, Sorbera C, et al. Efficacy of radiofrequency catheter ablation in treatment of elderly patients with supraventricular tachyarrhythmias and ventricular tachycardia. Am J Ther. 2006; 13:513-515.
61. Cox JL, Boineau JP, Schuessler RB, et al. Successful surgical treatment of atrial fibrillation: review and clinical update. JAMA. 1991;266:1976-1980.
62. Leitch JW, Klein G, Yee R, et al. Sinus node-atrioventricular node isolation: long-term results with the "Corridor" operation for atrial fibrillation. J Am Coll Cardiol. 1991;17:970-975.
63. Handa N, Scaff HV, Morris JJ, et al. Outcome of valve repair and the Cox maze procedure for mitral regurgitation and association atrial fibrillation. J Thorac Cardiovasc Surg. 1999;118:628-635.
64. McCarthy PM, Gillinov AM, Castle L, et al. The Cox-Maze procedure: the Cleveland Clinic experience. Semin Thorac Cardiovasc Surg. 2000; 12:25-29.
65. Jessurun ER, van Hemel NM, Defauw JA, et al. Results of maze surgery for lone paroxysmal atrial fibrillation. Circulation. 2000;101:1559-1567.
66. Naik S, Aronow WS, Fleisher AG. Intraoperative radiofrequency maze procedure for treating atrial fibrillation at the time of valve surgery or coronary artery bypass grafting. Am J Ther. 2006;13:298-299.
67. Gaita F, Gallotti R, Calo L, et al. Limited posterior left atrial cryoablation in patients with chronic atrial fibrillation undergoing valvular heart surgery. J Am Coll Cardiol. 2000;36:159-166.
68. Haissaguerre M, Jais P, Shah DC, et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation. 2000;101:1409-1417.
69. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. The APAF Study. J Am Coll Cardiol. 2006;48:2340-2347.
70. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation. A randomized trial. JAMA. 2005;293:2634-2640.
71. Arentz T, Weber R, Burkle G, et al. Small or large isolation areas around the pulmonary veins for the treatment of atrial fibrillation. Results from a prospective randomized study. Circulation. 2007;115:3057-3063.
72. Gaita F, Riccardi R. Catheter maze-ablation for preventing atrial fibrillation: where do we stand? Cardiac Electrophysiol Rev. 2001;5:231-233.
73. Wellens HJJ, Lau C-P, Luderitz B, et al. Atrioverter: an implantable device for the treatment of atrial fibrillation. Circulation. 1998;98:1651-1656.
74. Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation. Results from the international multi-center feasibility trials. J Am Coll Cardiol. 2005;46:9-14.
75. Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN Left Atrial Appendage System for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2007;49:1490-1495.
76. Sgarbossa EB, Pinski SL, Maloney JD, et al. Chronic atrial fibrillation and stroke in paced patients with sick sinus syndrome. Relevance of clinical characteristics and pacing modalities. Circulation. 1993;88: 1045-1053.
77. Andersen HR, Thuesen L, Bagger JP, et al. Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome. Lancet. 1994;344:1523-1528.
78. Aronow WS, Mercando AD, Epstein S. Prevalence of arrhythmias detected by 24-hour ambulatory electrocardiography and value of antiarrhythmic therapy in elderly patients with unexplained syncope. Am J Cardiol. 1992;70:408-410.
79. Coumel P, Friocourt P, Mugica J, et al. Long-term prevention of vagal atrial arrhythmias by atria pacing at 90/minute: experience with 6 cases. Pacing Clin Electrophysiol. 1983;6:552-560.
80. Gillis AM, Wyse DG, Connolly SJ, et al. Atrial pacing periablation for prevention of paroxysmal atrial fibrillation. Circulation. 1999;99:2553-2558.
81. Friedman PA, Hill MRS, Hammill SC, et al. Randomized prospective pilot study of long-term dual-site atrial pacing for prevention of atrial fibrillation. Mayo Clin Proc. 1998;73:848-854.
82. Lau C-P, Tse H-F, Yu C-M, et al. Dual-site atrial pacing for atrial fibrillation in patients without bradycardia. Am J Cardiol. 2001;88:371-375.
83. Levy T, Fotopoulos G, Walker S, et al. Randomized controlled study investigating the effect of biatrial pacing in prevention of atrial fibrillation after coronary artery bypass grafting. Circulation. 2000;102:1382-1387.
84. Patel AM, Westveer DC, Man KC, et al. Treatment of underlying atrial fibrillation: paced rhythm obscures recognition. J Am Coll Cardiol. 2000;36:784-787.
85. Knight BP, Gersh BJ, Carlson MD, et al. Role of permanent pacing to prevent atrial fibrillation. Science advisory from the American Heart Association Council on Clinical Cardiology (Subcommittee on Electrocardiography and Arrhythmias) and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm Society. Circulation. 2005;111:240-243.